Craif Inc. (AI) — Funding, Investors & Signals 2026

Craif Inc.

Harnessing the power of urinary miRNA to detect cancer early

Founded 2018

Irvine, United States 19 employees Non Equity Assistance Total: $11.35M AI, Health Care +1

Craif Inc. is a forward-looking startup dedicated to revolutionizing the early cancer diagnosis landscape through advanced urine testing techniques. The company's slogan, "Empowering a new era of early, painless, and precise cancer diagnosis," encapsulates its mission to eradicate the loss of lives to cancer. Founded in 2018, Craif is operating in the Health Care industry, focusing on developing a society where cancer diagnosis is painless and accurate. Craif recognizes the critical importance of early cancer detection, acknowledging that it can amplify survival rates and significantly enhance outcomes. With numerous cancers remaining asymptomatic until they reach advanced stages, the need for regular and precise diagnostic tests is more crucial than ever. The company aims to address the shortcomings of current diagnostic methods, which often prove painful and lack the essential accuracy for consistent and early-stage detection. In its journey to fulfill its vision, Craif recently secured a significant milestone with its Series B investment on 22 April 2022, with Global Brain coming on board as the investor. This strategic partnership is a testament to the potential recognized by leading investors in Craif's groundbreaking approach to cancer diagnosis.

Funding Stage	Amount	Investors	Lead Investors	Date
Non Equity Assistance	Undisclosed	1	MedTech Innovator	29 May 2024
Series B	Undisclosed	1	Global Brain	22 Apr 2022
Series B	$11.35M	5	Daiwa Corporate Investment, MTG Ventures +3	02 Nov 2021
Non Equity Assistance	Undisclosed	1	VentureOut	29 Sep 2020
Series A	Undisclosed	5	ANRI, Daiwa Corporate Investment +3	17 Jun 2020
Seed Round	Undisclosed	3	ANRI, NEDO +1	13 Feb 2019

Funding Stage

Amount

Investors

Lead Investors

Date

Non Equity Assistance

Undisclosed

MedTech Innovator

29 May 2024

Series B

Undisclosed

Global Brain

22 Apr 2022

Series B

$11.35M

Daiwa Corporate Investment, MTG Ventures +3

02 Nov 2021

Non Equity Assistance

Undisclosed

VentureOut

29 Sep 2020

Series A

Undisclosed

ANRI, Daiwa Corporate Investment +3

17 Jun 2020

Seed Round

Undisclosed

ANRI, NEDO +1

13 Feb 2019

FAQ About Craif Inc.

Harnessing the power of urinary miRNA to detect cancer early

Craif Inc. was founded in 2018.

Craif Inc. is headquartered in Irvine, United States.

Craif Inc. operates in AI, Health Care and Machine Learning. Its work centres on Cancer diagnosis, Early detection, Urine testing and Precision medicine.

Craif Inc. has approximately 19 employees.

Craif Inc. has completed 6 funding rounds, raising a total of $11.35M. The latest funding stage is Non Equity Assistance.

Top alternatives and competitors to Craif Inc. include CogniScent, Cyted Health, Artificial Intelligence Expert, Qritive, Sight Diagnostics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Craif Inc. and CogniScent are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Craif Inc.

General Information

Discover More

About Craif Inc.

Funding Rounds & Investors (6)

Craif Inc. Alternatives & Competitors

FAQ About Craif Inc.